Literature DB >> 9886600

The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia.

E Giovannucci1, E A Platz, M J Stampfer, A Chan, K Krithivas, I Kawachi, W C Willett, P W Kantoff.   

Abstract

OBJECTIVES: Shorter CAG repeat lengths in exon 1 of the androgen receptor (AR) gene are associated with a stronger transcriptional activity of the AR and with a higher risk of prostate cancer. Because benign prostatic hyperplasia (BPH) is an androgen-dependent condition, we examined the hypothesis that men with shorter AR gene CAG repeat lengths have an increased risk of developing BPH.
METHODS: Using data from the Health Professionals Follow-up Study (HPFS), we evaluated the relationship between AR gene CAG repeat length and prevalent BPH, as defined by BPH surgery, by enlarged prostate gland detected by digital rectal examination, and by urinary symptoms as determined by the American Urological Association Symptom Index.
RESULTS: The odds ratio for BPH surgery or enlarged prostate gland was 1.92 (95% confidence interval [CI] 1.22 to 3.03; P [trend] = 0.0002), comparing AR gene CAG repeat length of 1 9 or less to 25 or more. Results were similar for the end points of BPH surgery (P [trend] = 0.002) and for enlarged prostate gland (P [trend] = 0.001). For a six-repeat decrease in CAG repeat length, the odds ratio for having moderate or severe urinary obstructive symptoms from an enlarged prostate gland was 3.62 (95% CI 1.51 to 8.67; P = 0.004).
CONCLUSIONS: Variability in the AR gene CAG repeat influences the development of symptomatic BPH, particularly in predicting obstructive urinary symptoms. Our findings support further study to establish the appropriate clinical relevance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9886600     DOI: 10.1016/s0090-4295(98)00468-3

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  20 in total

1.  Decision tree-based modeling of androgen pathway genes and prostate cancer risk.

Authors:  Jill S Barnholtz-Sloan; Xiaowei Guan; Charnita Zeigler-Johnson; Neal J Meropol; Timothy R Rebbeck
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-04-14       Impact factor: 4.254

Review 2.  Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

Authors:  Tristan M Nicholson; William A Ricke
Journal:  Differentiation       Date:  2011-05-26       Impact factor: 3.880

3.  Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk.

Authors:  Kathryn L Terry; Immaculata De Vivo; Linda Titus-Ernstoff; Mei-Chiung Shih; Daniel W Cramer
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

4.  Androgen receptor polyglutamine repeat length affects receptor activity and C2C12 cell development.

Authors:  Ryan L Sheppard; Espen E Spangenburg; Eva R Chin; Stephen M Roth
Journal:  Physiol Genomics       Date:  2011-08-09       Impact factor: 3.107

Review 5.  Estrogen and androgen signaling in the pathogenesis of BPH.

Authors:  Clement K M Ho; Fouad K Habib
Journal:  Nat Rev Urol       Date:  2011-01       Impact factor: 14.432

6.  Fundamental aspects of hypogonadism in the aging male.

Authors:  Alvin M Matsumoto
Journal:  Rev Urol       Date:  2003

7.  Preeclampsia and androgen receptor gene CAG repeat length: results from both children and women.

Authors:  Tanja Saarela; Jarmo Jääskeläinen; Sirpa Tenhola; Raimo Voutilainen; Seppo Heinonen
Journal:  J Assist Reprod Genet       Date:  2005-08       Impact factor: 3.412

8.  Prostate cancer cognitive-behavioral factors in a West African population.

Authors:  Folakemi T Odedina; Daohai Yu; Titilola O Akinremi; R Renee Reams; Matthew L Freedman; Nagi Kumar
Journal:  J Immigr Minor Health       Date:  2008-12-04

9.  Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.

Authors:  Alan R Kristal; Douglas K Price; Cathee Till; Jeannette M Schenk; Marian L Neuhouser; Sandy Ockers; Daniel W Lin; Ian M Thompson; William D Figg
Journal:  Prostate       Date:  2010-05-01       Impact factor: 4.104

Review 10.  Advances in male contraception.

Authors:  Stephanie T Page; John K Amory; William J Bremner
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.